Ricchiuti V, Briand J P, Meyer O, Isenberg D A, Pruijn G, Muller S
Institut de Biologie Moléculaire et Cellulaire, UPR 9021 CNRS, Strasbourg, France.
Clin Exp Immunol. 1994 Mar;95(3):397-407. doi: 10.1111/j.1365-2249.1994.tb07010.x.
The reactivity of autoantibodies present in the sera of 489 patients with Sjögren's syndrome (SS), systemic lupus erythematosus (SLE) and other autoimmune diseases was investigated by ELISA using recombinant 52-kD SSA/Ro protein (rRo52) and 39 overlapping synthetic peptides representing the entire sequence of Ro52. We report that IgG antibodies reacting with rRo52 were present in the sera of a large number of patients with SS (67% of patients with primary SS and 46% of patients with SS associated with SLE), whereas they were less frequent (10-25%) in SLE, rheumatoid arthritis (RA), juvenile chronic arthritis (JCA) and mixed connective tissue disease (MCTD), and absent in scleroderma. Among the 39 peptides tested, five were recognized by sera from 30-65% of patients with SS, namely peptides representing residues 2-11, 107-122, 107-126, 277-292 and 365-382. Patients with JCA had raised levels of IgG antibodies reacting with peptides 2-11 and 365-382, and 51% of patients with MCTD had raised levels of IgG antibodies reacting with peptide 365-382. None of the five peptides was recognized by more than 20% of sera from patients with SLE and RA. Interestingly, and of importance in the field of diagnostic tests based on peptides, the reactivity of antibodies to the Ro52 synthetic peptides varied greatly according to the origin of sera. Inhibition experiments using either patients' sera or antibodies induced in rabbits against Ro52 peptides showed that the four domains 2-11, 107-122, 277-292 and 365-382 are accessible on the surface of the Ro52 protein. These regions may thus be involved in the induction of specific antibodies in autoimmune patients.
采用重组52-kD SSA/Ro蛋白(rRo52)和代表Ro52全序列的39个重叠合成肽,通过酶联免疫吸附测定(ELISA)研究了489例干燥综合征(SS)、系统性红斑狼疮(SLE)及其他自身免疫性疾病患者血清中自身抗体的反应性。我们报告,大量SS患者血清中存在与rRo52反应的IgG抗体(原发性SS患者中67%,与SLE相关的SS患者中46%),而在SLE、类风湿关节炎(RA)、青少年慢性关节炎(JCA)和混合性结缔组织病(MCTD)中出现频率较低(10%-25%),在硬皮病患者中则未检测到。在所检测的39个肽中,5个肽被30%-65%的SS患者血清识别,即代表第2-11位、107-122位、107-126位、277-292位和365-382位残基的肽。JCA患者中与第2-11位和365-382位肽反应的IgG抗体水平升高,51%的MCTD患者中与第365-382位肽反应的IgG抗体水平升高。5个肽中没有一个被超过20%的SLE和RA患者血清识别。有趣的是,在基于肽的诊断测试领域中很重要的是,针对Ro52合成肽的抗体反应性根据血清来源差异很大。使用患者血清或兔抗Ro52肽诱导的抗体进行的抑制实验表明,Ro52蛋白表面可及4个结构域,即第2-11位、107-122位、277-292位和365-382位。因此,这些区域可能参与自身免疫患者中特异性抗体的诱导。